CTOs on the Move

Standards Testing Laboratory

www.stllabs.com

 
STL now operates the world's largest independent dynamic testing facility for tires, wheels and related automotive components, providing the rubber and automotive industries with dynamic laboratory testing, static and physical testing, fleet testing,
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.stllabs.com
  • 1845 Harsh Ave SE
    Massillon, OH USA 44646
  • Phone: 330.833.8548

Executives

Name Title Contact Details

Similar Companies

Marketbase

Marketbase is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Laureate Pharma

Laureate Pharma L.P. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visterra Incorporated

Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company`s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company`s lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment of both seasonal and pandemic influenza, is in a phase 2a clinical trial and expected to enter a phase 2b clinical trial by year end 2017. The company`s second product candidate, VIS649, is a monoclonal antibody engineered to treat IgA nephropathy, a rare chronic kidney disease. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.

ABI Inc

ABI Inc is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.